Companies › Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
1 active drug program in 2 registered trials: 2 Phase 2; Immunology; next expected readout Sep 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MORF-057 Selective integrin α4β7 inhibitor | ITGA4, ITGB7 | Phase 2 | Inflammatory Bowel Diseases | Sep 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05611671 | MORF-057 | Phase 2 | Inflammatory Bowel Diseases | Immunology | Nov 2024 |
| NCT06226883 | MORF-057 | Phase 2 | Inflammatory Bowel Diseases | Immunology | Sep 2028 |
Calixis Qifeng Zhang Topadur Pharma Leadingtac Pharmaceutical (Shaoxing) Agomab Spain S.L.U.
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.